Omega emerges as direct secondary player

The firm, led by former AlpInvest life sciences specialist Otello Stampacchia, has agreed to acquire six ‘tail-end’ portfolio investments from Atlas Venture in a secondary transaction.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this